Thomas Albini on Angiogenesis '26: AI, GA Pipelines, Gene Therapy, and What Not to Miss

3/28/26

Guest: Thomas Albini, MD – Course Co-Leader, Angiogenesis, Exudation, and Degeneration Meeting

Show Summary

Thomas Albini, MD, joins John Kitchens, MD, and Scott Krzywonos to help listeners navigate the 2026 Angiogenesis, Exudation, and Degeneration meeting — a one-day, 80+-talk marathon that serves as a global preview of where retina research is heading.

The conversation covers the rapid expansion of AI in retina imaging and clinical trials, early-phase geographic atrophy data, durability strategies in wet AMD, and a packed slate of gene therapy and inherited retinal disease updates.

Tom also explains why the meeting remains fully virtual, how talks are selected, and how Angiogenesis fits alongside other major meetings in the retina calendar.

Topics Covered

  • Why the Angiogenesis meeting remains virtual — and how attendance has doubled

  • How to prepare for a one-day, 80+-talk retina marathon

  • The growing role of AI and machine learning in imaging and clinical trials

  • When AI may realistically impact everyday clinical practice

  • Early-phase geographic atrophy data and emerging systemic therapies

  • Oral and non-intravitreal treatment strategies — and their safety tradeoffs

  • Complement vs. non-complement targets in GA

  • Advances in wet AMD durability

  • What to watch in gene therapy, including delivery routes and inflammation risk

  • Inherited retinal disease sessions, including optogenetics and gene-agnostic approaches

  • Home OCT, imaging innovation, and AI-inferred fluorescein angiography

  • Landmark trials reaching their final chapters — and why they matter

  • How Angiogenesis fits alongside meetings like ASRS, AAO, and the Vit-Buckle Society

Key Quotes

"You could say this is a lot of [AI] talks, but I think it's the tip of the iceberg. I would imagine it's going to grow exponentially over the years." — Thomas Albini, MD

"If there's any hour to not miss in this meeting, I've bookmarked that 2:45 to 3:45 hour because you literally get every single gene therapy talk in a single hour." — John Kitchens, MD

Previous

Breaking News: SOL-1 Superiority Data for Axpaxli in Wet AMD

Next

Elizabeth Cifers on Coding Risk, Modifier -25 Enforcement, and the Rise of Pre-Pay Audits